{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Zhang R"],"pubmed_abstract":["Evolution of SARS-CoV-2 variants emphasizes the need for multivalent vaccines capable of simultaneously targeting multiple strains. SCTV01E is a tetravalent COVID-19 vaccine derived from the spike protein of SARS-CoV-2 variants Alpha, Beta, Delta, and Omicron BA.1. In this double-blinded placebo-controlled pivotal efficacy trial (NCT05308576), the primary endpoint was vaccine efficacy (VE) against COVID-19 seven days post-vaccination in individuals without recent infection. Other endpoints included evaluating safety, immunogenicity, and the VE against all SARS-CoV-2 infections in individuals meeting the study criteria. Between December 26, 2022, and January 15, 2023, 9,223 individuals were randomized at a 1:1 ratio to receive SCTV01E or a placebo. SCTV01E showed a VE of 69.4% (95% CI: 50.6"],"journal":["Nature communications"],"pagination":["6255"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11269576"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial."],"pmcid":["PMC11269576"],"pubmed_authors":["Gan B","Zhao W","Gao J","Wu B","Cao F","Liu S","Zhang R","Wang J","Liu Y","Xie G","Wang S","Chen Y","Bai J","Wang Y","Zhao J","Yan L","Qian G","Li J","Zhou Q","Li D","Tan J","Xie L","Guan Q","Li M","Li W","Gai W","Li X","Tian X","Xu S","Zhu X","Liu C","Liu D","Jiao Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial.","description":"Evolution of SARS-CoV-2 variants emphasizes the need for multivalent vaccines capable of simultaneously targeting multiple strains. SCTV01E is a tetravalent COVID-19 vaccine derived from the spike protein of SARS-CoV-2 variants Alpha, Beta, Delta, and Omicron BA.1. In this double-blinded placebo-controlled pivotal efficacy trial (NCT05308576), the primary endpoint was vaccine efficacy (VE) against COVID-19 seven days post-vaccination in individuals without recent infection. Other endpoints included evaluating safety, immunogenicity, and the VE against all SARS-CoV-2 infections in individuals meeting the study criteria. Between December 26, 2022, and January 15, 2023, 9,223 individuals were randomized at a 1:1 ratio to receive SCTV01E or a placebo. SCTV01E showed a VE of 69.4% (95% CI: 50.6","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T06:55:35.059Z","creation":"2025-04-19T13:11:29.694Z"},"accession":"S-EPMC11269576","cross_references":{"pubmed":["39048547"],"doi":["10.1038/s41467-024-49832-7"]}}